In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data regulatory actions or delays or government regulation generally global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency our ability to obtain or maintain proprietary intellectual property protection the particular prescribing preferences of physicians and patients general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19 safety, quality, data integrity or manufacturing issues potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Nor can there be any guarantee that such products will be commercially successful in the future. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. You should not place undue reliance on these statements. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "seek," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. 5 This is why faster, accurate diagnosis is essential to offering patients the best possible outcome. 4 Because NETs can be misdiagnosed or where there is a delay in diagnosis, the tumour is likely to spread to other parts of the body. Alarmingly, of the approximately 12,000-15,000 Canadians with NETs, only 10% have a complete and accurate diagnosis. 3 The prevalence of neuroendocrine tumours (NET) is estimated at 35 per 100,000 but may be considerably higher if undiagnosed tumours are included. The increased incidence refutes the reference to these cancers as rare. These cancers are the second most common type of gastrointestinal malignancy and NETs are now the fastest growing class of cancers worldwide, accounting for approximately 2% of cancers. NETs can remain clinically silent for years thus delaying diagnosis. Neuroendocrine tumours, also known as NETs, are a group of tumours that can originate in the neuroendocrine cells of many different organs such as the stomach, intestines, pancreas, lungs and other locations. In addition, the approval reflects our ongoing commitment to the Canadian neuroendocrine tumour community, including patients, their families and the healthcare professionals dedicated to their care," said Lyndal Walker, General Manager of Advanced Accelerator Applications in Canada. "We are excited about the approval of NETSPOT ® as it offers physicians additional insight into the patient's disease burden, enabling them to optimize treatment and care. "We applaud Health Canada in approving the NETSPOT ® kit and this innovative technology as an important adjunct to helping physicians identify the precise location and extent of the tumour and plan staging and the best course of treatment," stated Jackie Herman, President & Director of Treatment Access & Health Policy of CNETS Canada.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |